Clinical Edge Journal Scan

Psoriasis affects well-being and clinical outcomes in juvenile PsA


 

Key clinical point: Children and young people with juvenile psoriatic arthritis (JPsA) have poorer well-being than other subsets of juvenile idiopathic arthritis (JIA), with having psoriasis at JPsA diagnosis linked with more depressive symptoms.

Major finding: Children with JPsA vs other JIA categories had 2.35-times higher odds of having persistently poor well-being scores despite improvements in joint counts and physician global scores (P = .013), and children with psoriasis at JPsA diagnosis scored, on average, 10 points higher on the baseline Moods and Feelings Questionnaire (co-efficient 9.77; P = .039).

Study details: This study evaluated 1653 children and young people with JIA who were recruited to the Childhood Arthritis Prospective Study, of whom 111 had JPsA at diagnosis.

Disclosures: This study was funded by the Cecil King Memorial Fund and other sources. The authors declared no conflicts of interest.

Source: Low JM et al for the CAPS Principal Investigators. The impact of psoriasis on wellbeing and clinical outcomes in juvenile psoriatic arthritis. Rheumatology (Oxford). 2023 (Jul 19). doi: 10.1093/rheumatology/kead370

Recommended Reading

Real-world study highlights heterogeneity of disease domains in PsA
MDedge Rheumatology
Clinical and laboratory biomarkers that may help early PsA diagnosis
MDedge Rheumatology
Serum neutrophil gelatinase-associated lipocalin levels show no correlation with PsA outcomes
MDedge Rheumatology
Vitamin D deficiency linked to psoriasis severity
MDedge Rheumatology
Could risk stratifying methotrexate users lead to less frequent testing?
MDedge Rheumatology
Commentary: PsA domains and analysis of various biologics in PsA, August 2023
MDedge Rheumatology
What factors cause multiple biologic failure in psoriasis?
MDedge Rheumatology
Study validates use of new psoriatic arthritis prediction tool
MDedge Rheumatology
PsA biomarkers move researchers closer to predictive test
MDedge Rheumatology
DNA methylation markers may predict PsA development in patients with psoriasis
MDedge Rheumatology